当前位置: 首页 > 期刊 > 《医学信息》 > 2019年第17期
编号:13424858
晚期结直肠癌抗血管生成靶向治疗研究进展(5)
http://www.100md.com 2019年4月30日 《医学信息》 2019年第17期
     [23]Van Cutsem E,TabemeroJ,Lakomy R,et al.Additionof aflibercept to fluorouracil,leucovorin,an d irinotecan improves survival in aphaseⅢrandomized tril in patients with metastatic colorectal cancer previously treated with anoxaliplatin-based regimen[J].J Clin Oncol,2012,30(28):3499-3506.

    [24]Grothey A,Van Cutsem E,Sobrero A,et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT):aninternational, multicentre,randomised,placebo-controlled,phase 3 trial[J].Lancet,2013,381(9863):303-312.

    [25]Li W,Zhao X,Du B,et al.Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy[J].Sci Rep,2016(6):30619.

    [26]何朗,孫永红,蒋莉,等.rh-Endostatin与肿瘤血管正常化时相的关系初探[J].中华肿瘤防治杂志,2016,23(19):1291-1297.

    [27]Wang J,Xiao J,Wei X,et al.Circulating endothelial cells and tumor blood volume as predictors in lung cancer[J].Cancer Sci,2013,104(4):445-452.

    [28]潘永勤,焦根龙.恩度联合化疗治疗晚期结直肠癌的近期疗效的Meta分析[J].南方医科大学学报.2014,34(2):270-274.

    [29]Li L,Huang XE.Thalidomide combined with chemotherapy in treating patients with advanced lung cancer[J].Asian Pac J Cancer Prev,2016,17(5):2583-2585.

    收稿日期:2019-5-24;修回日期:2019-6-10

    编辑/肖婷婷, 百拇医药(孙峰 鲍扬漪 朱婷)
上一页1 2 3 4 5